Novavax Payout Ratio vs Price To Sales Ratio Analysis
NVAX Stock | USD 18.17 1.39 7.11% |
Novavax financial indicator trend analysis is infinitely more than just investigating Novavax recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novavax is a good investment. Please check the relationship between Novavax Payout Ratio and its Price To Sales Ratio accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.
Payout Ratio vs Price To Sales Ratio
Payout Ratio vs Price To Sales Ratio Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novavax Payout Ratio account and Price To Sales Ratio. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Novavax's Payout Ratio and Price To Sales Ratio is -0.17. Overlapping area represents the amount of variation of Payout Ratio that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Novavax, assuming nothing else is changed. The correlation between historical values of Novavax's Payout Ratio and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Payout Ratio of Novavax are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Payout Ratio i.e., Novavax's Payout Ratio and Price To Sales Ratio go up and down completely randomly.
Correlation Coefficient | -0.17 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Payout Ratio
Payout Ratio is the proportion of Novavax earnings paid out as dividends to shareholders. Payout Ratio is typically expressed as a percentage but can be shown as dividends paid out as a proportion of cash flow. The payout ratio is used to determine the sustainability of Novavax dividend payments. A lower payout ratio is generally preferable to a higher payout ratio, with a ratio greater than 100% indicating Novavax is paying out more in dividends than it makes in net income.Price To Sales Ratio
Price to Sales Ratio is figured by comparing Novavax stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Novavax sales, a figure that is much harder to manipulate than other Novavax multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.Most indicators from Novavax's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novavax current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.At this time, Novavax's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 442.5 M in 2024, despite the fact that Tax Provision is likely to grow to (1.8 M).
Novavax fundamental ratios Correlations
Click cells to compare fundamentals
Novavax Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novavax fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 173.0M | 1.6B | 2.6B | 2.3B | 1.9B | 1.9B | |
Other Current Liab | 19.9M | (327.6M) | 709.8M | 1.5B | 1.2B | 1.3B | |
Total Current Liabilities | 25.8M | 322.0M | 2.4B | 2.5B | 1.6B | 1.7B | |
Total Stockholder Equity | (186.0M) | 627.2M | (351.7M) | (634.1M) | (716.9M) | (681.1M) | |
Property Plant And Equipment Net | 11.4M | 180.0M | 228.7M | 400.5M | 491.0M | 515.5M | |
Net Debt | 243.1M | (231.4M) | (1.1B) | (787.1M) | (298.3M) | (283.4M) | |
Retained Earnings | (1.4B) | (1.9B) | (3.6B) | (4.3B) | (4.8B) | (4.6B) | |
Accounts Payable | 2.9M | 54.3M | 127.1M | 216.5M | 132.6M | 139.2M | |
Cash | 78.8M | 553.4M | 1.5B | 1.3B | 578.9M | 607.9M | |
Non Current Assets Total | 75.7M | 334.3M | 421.6M | 555.3M | 711.5M | 747.0M | |
Non Currrent Assets Other | 7.5M | 13.2M | 56.7M | 28.5M | 30.3M | 31.8M | |
Cash And Short Term Investments | 78.8M | 711.0M | 1.5B | 1.3B | 578.9M | 607.9M | |
Common Stock Shares Outstanding | 24.1M | 57.6M | 74.4M | 78.2M | 100.8M | 105.8M | |
Liabilities And Stockholders Equity | 173.0M | 1.6B | 2.6B | 2.3B | 1.9B | 1.9B | |
Other Current Assets | 93.9M | 441.8M | 2.1B | 1.7B | 226.0M | 191.7M | |
Other Stockholder Equity | 1.3B | 2.5B | 3.3B | 3.6B | 4.1B | 4.3B | |
Total Liab | 359.0M | 955.3M | 2.9B | 2.9B | 2.6B | 2.7B | |
Property Plant And Equipment Gross | 11.4M | 180.0M | 258.6M | 447.8M | 566.0M | 594.3M | |
Total Current Assets | 97.2M | 1.2B | 2.2B | 1.7B | 1.1B | 1.2B | |
Accumulated Other Comprehensive Income | (12.5M) | 7.0M | (1.4M) | (6.4M) | 2.7M | 2.9M | |
Net Receivables | 7.5M | 262.0M | 455.0M | 82.4M | 297.2M | 312.1M | |
Non Current Liabilities Total | 333.2M | 633.2M | 538.1M | 432.8M | 937.1M | 984.0M | |
Intangible Assets | 6.5M | 5.6M | 5.7M | 4.8M | 4.3M | 4.1M | |
Short Long Term Debt Total | 321.9M | 322.0M | 454.0M | 549.8M | 280.6M | 294.7M | |
Common Stock Total Equity | 3.8M | 324K | 714K | 764K | 878.6K | 1.3M | |
Short Term Debt | 1.3M | 322.0M | 130.5M | 352.1M | 28.1M | 43.9M | |
Common Stock | 324K | 714K | 764K | 868K | 1.4M | 1.3M | |
Long Term Debt | 320.6M | 322.0M | 323.5M | 166.5M | 168.0M | 114.6M | |
Inventory | (83.0M) | (166.7M) | (2.0B) | 36.7M | 41.7M | 43.8M | |
Property Plant Equipment | 11.4M | 180.0M | 228.7M | 400.5M | 460.6M | 483.6M | |
Other Liab | 2.6M | 3.4M | 175.5M | 185.0M | 212.8M | 223.4M | |
Current Deferred Revenue | 1.7M | 273.2M | 1.4B | 370.1M | 241.3M | 140.2M | |
Other Assets | 1.1M | 5.4M | 16.6M | 28.5M | 32.7M | 34.4M | |
Good Will | 51.2M | 135.4M | 131.5M | 126.3M | 127.5M | 133.8M | |
Net Tangible Assets | (242.8M) | 486.1M | (487.9M) | (760.4M) | (684.4M) | (650.1M) | |
Retained Earnings Total Equity | (1.3B) | (1.4B) | (1.9B) | (3.6B) | (3.3B) | (3.1B) | |
Long Term Debt Total | 319.2M | 320.6M | 322.0M | 323.5M | 372.0M | 234.9M | |
Capital Surpluse | 1.1B | 1.3B | 2.5B | 3.4B | 3.9B | 4.0B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.